HPTN 059
Status:Completed
Phase:II
Principal Investigator(s):Sharon Hillier, PhD; Jessica Justman, MD; Smita N. Joshi, MBBS; Craig Hoesley, MD
Objective:The purpose of this study is to determine the safety and acceptability of a vaginal microbicide in HIV uninfected sexually active women.
Last updated May 16, 2021
Prevention Option(s):Microbicides
Study Design:Controlled, Double-blind, Placebo
Arms and Assigned Interventions
DescriptionDrug: 1% tenofovir gel
Mode of DeliveryGel
ARMs
Official Code:
NCT00111943
Trial Sponsors:
NIAID (DAIDS-ES: 10145)
Start Date
End Date
none
October 2, 2007
Enrollment:200
Age range:
18 Years ↔
50 Years
Population:Cisgender Women